June 30, 2021

CureLab Oncology Submits Patent for COVID Therapeutic Ahead of Phase I Clinical Trials

CureLab Oncology intends to determine whether its Elenagen DNA vaccine can be used to reduce severity, mortality and life-threatening post-COVID complications.
March 15, 2021

CureLab Oncology adds Hong Kong to expanding scope of patent protection

Patent registration in Hong Kong paves the way to establishing business operations in PRC
January 22, 2021

Curelab Veterinary Launches in Animal Health Sector, Leveraging Technology Licensed from CureLab Oncology

Based on a scientifically solid proof of concept in dogs and cats, a licensed international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding and to become profitable within 36 months of raising funds.
November 10, 2020

CureLab Oncology Establishes Operations in Europe

CureLab is expanding its global presence with a new office from which it will base operations in the European Union; Ricarda Cramer joins as business development director
October 21, 2020

CureLab Oncology Establishes Operations in the Gulf Region

CureLab is expanding its global presence with a new office in the Gulf Cooperation Council (GCC) region; CureLab's partners in the region will test the efficacy of the company's DNA-based products against cancers and non-cancerous diseases of chronic inflammation